Research
Hormonal
GLP-1 agonists (semaglutide and liraglutide) produce significant weight loss (approx. 8-16%) and improve glycemic control in obese patients, particularly those with type 2 diabetes or insulin resistance.
If you have obesity and type 2 diabetes or insulin resistance, GLP-1 agonists like semaglutide are highly effective for weight loss and blood sugar control. Discuss with your doctor if you are a candidate, especially if lifestyle changes alone have not been sufficient after 12 months.
GoodSupportsHIGH confidence
obese patients with type 2 diabetes or insulin resistance seem to benefit from LC diet combined with a GLP-1 agonist, e.g. semaglutide, which may improve glycemic control, stimulate satiety, and suppress appetite.
Why this rating
The paper cites multiple phase-3 trials and meta-analyses showing consistent results.
Source
Diets and drugs for weight loss and health in obesity – An update
Jan Aaseth et al. · Biomedicine & Pharmacotherapy · 2021
DOI 10.1016/j.biopha.2021.111789
narrative_reviewCited 174×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Low-carbohydrate diets (LCDs) and low-fat diets (LFDs) result in equivalent weight loss when caloric restriction is matched, though LCDs may be preferred for patients with insulin resistance.Good
- Bupropion-naltrexone combination therapy produces significant weight loss (approx. 6%) by interrupting the cycle of addictive over-eating through synergistic appetite suppression.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →